ENTER
  • Scientific rationale

    Breast cancer research has been the frontrunner in many fields of cancer research: epidemiology, life-style and genetic risk factors, secondary prevention, conservative surgery, molecular classification, curative adjuvant therapies, neoadjuvant treatments, targeted agents, survival prolongation in advanced stages. 
    Thanks to this knowledge, today many breast cancers can be prevented, most can be diagnosed at early stages and cured and the minority of patients at advanced stages can still enjoy a significant survival with a reasonable quality of life.
    As a consequence of these major improvements, the bar of research and clinical excellence for breast cancer has raised even more. New prognostic and predictive biomarkers are available, need to be validated and to be implemented in trial design and clinical practice. Risk-adapted surgery and radiation therapy allow for less and less invasive procedures. Multiple effective adjuvant therapies in the different molecular breast cancer subtypes, require a more precise definition of risk and predictivity of drug efficacy, to allow for a rational de-escalation or escalation of curative treatments. The impressive advances in the treatment of advanced breast cancers, envisage the possibility of cure with a multimodality approach for some patients and guarantee a prolonged survival for most of them with a rational sequencing of treatments.
    The 19th AIBCC in Padova, will allow to sum up the most recent biological and clinical achievements and to allow an open and friendly discussion of clinical cases among key opinion leaders and participants.

  • How to participate the meeting

    Enrollment in the course can only be done through the online procedure, no new registrations will be accepted at the congress venue.

    For access to the conference spaces, AccMed recommends adhering to the following safety rules:

    • do not enter the conference spaces with a body temperature above 37.5

    • maintain interpersonal distance

    • wear the FFP2 mask covering the nose and mouth for the entire duration of the activity

    • frequently disinfect hands with special hydroalcoholic gels

    You can find further details on the conduct of the event and related security measures here: https://fad.accmed.org/sicurezza.

  • Programme

    10.00  

     Introduction to the Conference

               

    Pierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat

    SESSION I – EVOLVING KNOWLEDGE OF BREAST CANCER BIOLOGY: IMPLICATIONS FOR STAGING, PROGNOSIS AND PREDICTION 

    Chairpersons: Maria Vittoria Dieci, Hesham Ahmed Gaballah Elghazaly
    10.30    

    Gene expression tools in early-stage HR+/HER2- breast cancer: when and which one?

     

    Gaia Griguolo
    11.00   

     Biological insights of the immune system in breast cancer

    Maria Vittoria Dieci
    11.30    

    DNA NGS-based biomarkers in advanced breast cancer: how, where and which ones?

    Mafalda Oliveira
    12.00    

    Tackling diversity in HER2-positive breast cancer: biological and clinical implications

     

    Tomas Pascual
    12.30   

     Discussion

    13.00    

    Lunch

    SESSION II – CHANGING PARADIGMS FOR LOCOREGIONAL TREATMENTS
    The changing relationship between locoregional recurrences and long-term outcomes
     

    Chairpersons: Oreste Gentilini, Jacek Jassem, Eleftherios Mamounas
    14.00   

     Mapping local and regional recurrences

    Orit Kaidar-person
    14.30    

    The surgical perspective

    Eleftherios Mamounas
    15.00   

     Deciphering the EBCTCG meta-analyses

    Philip Poortmans
    15.30    

    Discussion

    Multidisciplinary Tumor Board 1 – Locoregional treatment

    Panelists: Bettina Borisch, Oreste Gentilini, Jacek Jassem, Eleftherios Mamounas, Orit Kaidar-Person, Philip Poortmans, Hesham Ahmed Gaballah Elghazaly
    16.00  

    Clinical case 1. Skin flap thickness for IBR 

    Rosa Di Micco
    16.15    

    Clinical case 2. When to resect/irradiate after systemic therapy for a recurrence 

    Luca Visani
    16.30    

    Clinical case 3: Local recurrence after DCIS 

    Eleonora Ferrara
    16.45    

     General discussion and concluding comments

    Jacek Jassem, Hesham Ahmed Gaballah Elghazaly
    17.00   

     Adjourn

    17.15 

    Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2023 

    17.30    

    Lecture of the Awardee

    18.00    

    Adjourn

    SESSION III – EARLY BREAST CANCER

    Chairpersons: Alessandra Gennari, Valentina Guarneri
    9.00     

    New therapeutic strategies in very young women: lights and shadows

               

    Angela Toss
    9.20

    Elderly patients: how old is too old in the contemporary scenario

       

    Laura Biganzoli
    9.40    

     Neoadjuvant approach: rethinking the paradigm?

    Federica Miglietta
    10.00

    New ESMO Guidelines

          

    Sibylle Loibl
    10.20    

    Discussion

     

    10.50    

    Coffee break

    Multidisciplinary Tumor Board 2 - Early breast cancer

    Panelists: Maria Vittoria Dieci, Alessandra Gennari, Valentina Guarneri, Eleftherios Mamounas, Sibylle Loibl, Philip Poortmans
    11.15    

    Genomic test in premenopausal patients

           

    Davide Massa
    11.30    

    Adjuvant CDK 4/6 in patients with potential clinical indication but with low genomic risk

           

    Michele Bottosso
    11.45    

     HER2+ pt1cN0: adjuvant or neoadjuvant?

      

    Ottavia Amato
    12.00    

    General discussion and concluding comments 

    Alessandra Gennari
    12.30    

    Lunch

    SESSION IV – METASTATIC BREAST CANCER: NEW OPTIONS, NEW ALGORITHMS 

    Chairpersons: Giuseppe Curigliano, Pierfranco Conte
    13.30    

    HR+ disease: is there any preferred treatment sequence at the time of endocrine-resistance?

    Stephen Johnston
    14.00    

    HER2+ disease: from guidelines to a personalized approach based on tumor and patient characteristics

                

    Sandra Swain M
    14.30   

    Triple negative disease: something more than label indications to dictate treatment sequence?

              

     

    Hope Rugo
    15.00   

    Discussion

    Multidisciplinary Tumor Board 3 – Metastatic Breast Cancer  
              

    Panelists: Pierfranco Conte, Giuseppe Curigliano, Stephen Johnston, Hope Rugo, Sandra Swain
    15.30    

    Visceral crisis

    Grazia Vernaci
    16.00    

    Leptomeningeal metastases

    Cristina Falci
    16.15    

    General discussion and concluding comments

    Carlo Alberto Giorgi
    16.30   

     Take home messages and adjourn

          

    Pierfranco Conte, Valentina Guarneri, Aleix Prat, Philip Poortmans

  • Registration

    Participation registration fees

    • Quota di partecipazione intera € 120.00
    • Per specializzandi € 80.00

    For eligibility criteria and other information on reduced fees (if applicable), contact info.bologna@accmed.org.

    To participate in the event, it is necessary to complete the registration procedure (including payment of the applicable fee). Payment can be made online exclusively with Credit Cards or Paypal.

    If the minimum number of participants is not reached, the Academy reserves the right to cancel the activity. In this case, Accademia will proceed with the appropriate communication and full refund of the participation fees.

    In case of withdrawal, please inform AccMed promptly. If the waiver occurs within the 10th day prior to the start date of the event, the amount paid will be returned with the deduction of 30%. If the waiver occurs after that deadline, no reimbursement will be provided.

  • Training objective

    Contenuti tecnico-professionali (conoscenze e competenze) specifici di ciascuna professione, di ciascuna specializzazione e di ciascuna attività ultraspecialistica, ivi incluse le malattie rare e la medicina di genere

  • CME Instructions

    To obtain CME credits, users must meet the following requirements:

    1. Their declared profession/specialization must correspond to those accredited for CME.
    2. They must attend at least 90% of the course.
    3. They must complete the online meeting evaluation form.
    4. They must pass the learning assessment test with at least 75% correct answers. Only one attempt is allowed.

    The learning assessment test and meeting evaluation form must be submitted within three days of the event.

    Please note that in order to access the learning assessment test, users must (A) register at the course venue and (B) submit the online meeting evaluation form.

    Certificate of attendance 
    To download the certificate of attendance, users must have registered at the course venue.
    If their attendance is less than 75% of the stated duration, the certificate will reflect the percentage of attendance.
    We strongly encourage users to keep track of their personal badge and the badge recordings by the AccMed personnel, it is users' responsibility to have their attendance recorded accurately.